Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co. reported a slight decline in revenue for the third quarter of FY 2024, with a 1% decrease compared to the previous year. Despite challenges in prescription drug sales, the company saw a substantial increase in royalty income, particularly from its HIV franchise, which contributed significantly to its overall profitability.
More about Shionogi & Co
Shionogi & Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of prescription drugs, particularly in the infectious disease sector. The company also engages in overseas subsidiaries and exports, alongside earning significant revenue from royalty income, primarily from its HIV franchise.
YTD Price Performance: 20.32%
Average Trading Volume: 531
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $13.36B
See more data about 4507 stock on TipRanks’ Stock Analysis page.